Drug Topics
JULY 1, 2024
Drug Topics sat down with Sandra Canally, RN, founder and CEO of The Compliance Team, and Kara Benson, PharmD, long-term care director of Lewis Drug Inc, to discuss the future of LTC pharmacy.
STAT
JULY 5, 2024
New research finds that the GLP-1 class of drugs — glucagon-like peptide receptor agonists — is more effective in mitigating the risk of 10 obesity-associated cancers than its type 2 diabetes drug alternatives. The retrospective study, published Friday in JAMA Network Open , measured results for a cohort of more than 1.6 million patients with type 2 diabetes from 2005 to 2018 who were prescribed GLP-1s, insulin, or metformin.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 1, 2024
Additionally, birth weight was higher in babies born to mothers who were prescribed glucagon-like peptide-1 (GLP-1) medications either 90 days prior to pregnancy or during the first trimester.
Fierce Pharma
JULY 2, 2024
After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy—and a competitor to Eisai and Bioge | After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy, a competitor to Eisai and Biogen’s Leqembi, a full approval.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
JULY 4, 2024
“Adding this technology to our pandemic flu toolkit enhances our ability to be nimble and quick against the circulating strains and their potential variants,” said Dawn O’Connell, assistant secretary for preparedness and response at the HSS.
STAT
JULY 3, 2024
Remember when we thought Covid was a two-week illness? So does Michael Peluso, assistant professor of medicine at the University of California, San Francisco. He recalls the rush to study acute Covid infection, and the crush of resulting papers. But Peluso, an HIV researcher, knew what his team excelled at: following people over the long term.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JULY 2, 2024
Donanemab-azbt is the first and only amyloid plaque targeting therapy that supports stopping therapy when the plaque is removed.
Drug Topics
JULY 3, 2024
Individuals who ate diets that aligned closer to DASH and Mediterranean guidelines had lower levels of plasminogen activator inhibitor-1 and homocysteine biomarkers.
STAT
JULY 3, 2024
A new observational study on Wednesday reported for the first time a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss. After hearing anecdotes of patients on the diabetes and obesity drugs experiencing nonarteritic anterior ischemic optic neuropathy, or NAION, researchers at Massachusetts Eye and Ear analyzed data from a registry of patients at their institution to see if there was a broad trend.
Fierce Healthcare
JULY 3, 2024
To address behavioral health access barriers for students, California launched a program to offer incentive payments to Medi-Cal managed care plans to build capacity for behavioral health services in K-12 schools.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
JULY 4, 2024
Changing Faces explores the digital and supplier hires from April 2024, with a focus on companies like SPT Labtech, Sphere Fluidics, Newel Health, and Diaceutics. Stay updated on the latest developments in the industry.
Drug Topics
JULY 1, 2024
Research presented at the American Diabetes Association 84th Scientific Sessions suggests a population approach to CGM use could be beneficial.
STAT
JULY 3, 2024
When, in April, the federal government began requiring some cows to be tested for a strain of avian flu before their herds could be moved across state lines, it seemed like an obvious step to try to track and slow the virus that had started spreading among U.S. dairy cattle. But Joe Armstrong, a veterinarian at the University of Minnesota extension school, feared the U.S.
Fierce Healthcare
JULY 1, 2024
Digital primary care startup K Health raised $50 million in an equity funding round to build out its AI-powered medical services and fuel its growth, the company announced Monday. | Digital primary care startup K Health raised $50 million in an equity funding round to build out its AI-powered medical services and fuel its growth, the company announced Monday.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
pharmaphorum
JULY 1, 2024
ASCO 2024 conference highlights the latest advancements in oncology, emphasising the art and science behind enhanced cancer care. Stay updated on the latest research, treatments, and innovations in the field of oncology.
Drug Topics
JULY 2, 2024
Three posters presented at the American Diabetes Association 84th Scientific Sessions examined GLP-1 use and cardiovascular disease risk in several different patient populations.
STAT
JULY 2, 2024
As the H5N1 bird flu outbreak in dairy cows enters its fourth month, the Centers for Disease Control and Prevention is taking steps to ramp up the nation’s capacity to test for the virus in people. In a call with reporters Tuesday, Nirav Shah, the CDC’s principal deputy director, emphasized that the risk to the general public remains low at this time.
Fierce Healthcare
JULY 2, 2024
The House Ways and Means Committee advanced bipartisan legislation on Thursday that would grant Medicare coverage to novel medical technologies for four years while the Centers for Medicare & M | The House Ways and Means Committee advanced updated legislation to expedite Medicare coverage of breakthrough medical devices. The new version of the bill reduces its cost by 75%, according to co-sponsor Rep.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
JULY 2, 2024
The field of muscle stem cell research has been tangibly developing over the decades and in today’s pharmaphorum podcast wed editor Nicole Raleigh speaks with Dr Michael Rudnicki, co-founder and CSO of Satellos Biosciences, a company dedicated to developing novel therapeutics based on this science for those who live with Duchenne muscular dystrophy (DMD) and other degenerative muscle diseases.
Drug Topics
JUNE 29, 2024
Check out a recap of important pharmacy news you might have missed this week, dispensed in small doses.
STAT
JULY 1, 2024
Bird flu snapshot: This is the latest installment in a series of regular updates on H5N1 avian flu that STAT is publishing on Monday mornings. To read future updates you can also subscribe to STAT’s Morning Rounds newsletter. When pathologist Thijs Kuiken looks at what’s happening in the U.S. response to the H5N1 bird flu outbreak in dairy cows, he’s reminded of a difficult period in the Netherlands, where he lives, back in the late aughts.
Fierce Healthcare
JULY 3, 2024
LAS VEGAS—Amazon is betting big on its pharmacy arm, with the retail giant aiming to bring its focus on ease of use for consumers to the prescription drug space. | LAS VEGAS—Amazon is betting big on its pharmacy arm, with the retail giant aiming to bring its focus on ease of use for consumers to the prescription drug space.
Pharmacy Times
JULY 2, 2024
Artificial intelligence (AI) may optimize cash pricing strategies in community pharmacies.
Drug Topics
JULY 2, 2024
Donanemab-azbt was approved under the FDA's Fast Track Review, Priority Review, and Breakthrough Therapy designations.
STAT
JULY 1, 2024
For 15 years, a formidable CEO-CFO duo often called “the two Tonys” ushered their St. Louis-based health system through a period of explosive growth, adding hospital after hospital until it became one of the country’s biggest health systems. The year after former CEO Anthony Tersigni and former finance chief Anthony Speranzo stepped down, their sprawling empire of roughly 140 hospitals underwent the ultimate stress test: the Covid-19 pandemic.
Fierce Healthcare
JULY 3, 2024
A recent proposal to report prior authorization to insurance plans through CPT codes was withdrawn at the eleventh hour when its physician advocate made an unexpected discovery: For certain codes a | The advocate for a plan to reimburse physicians for time spent on rigorous claims learned that six CPT codes already include language about prior authorization.
European Pharmaceutical Review
JULY 4, 2024
Altering the conditions that T cells are grown in can improve CAR T-cell therapy, US researchers have found. Discovered by chance, their new method has potential to treat solid cancer tumours more efficiently, according to the findings. Putting T cells on a keto diet [putting our T cells on a three-day ‘keto’ diet] showed reduced maturity at the end of the manufacturing process.
pharmaphorum
JULY 3, 2024
Frontiers Health, a prominent event in health innovation, has unveiled the foundational pillars that will define its legacy and future trajectory. The announcement of these pillars precedes their global conference, scheduled for the 17th and 18th of October in Berlin.
STAT
JULY 2, 2024
Why do Americans pay so much more for common medications than people in other countries? Why does an inhaler that costs $7 in France cost almost $500 in the United States? These are just a few of the questions the Senate Judiciary Committee looked to answer in a recent hearing. The common answer? Dominant corporations use a variety of patent-related strategies to protect their power, maximize their profits, and squash their competition.
Fierce Healthcare
JULY 2, 2024
It didn’t take long for hospitals to bring the Supreme Court’s dismantling of the Chevron deference into their crusade against the formula for disproportionate share hospital (DSH) payments. | The complaint questioning CMS' formula for enhanced rates was filed the same day the Supreme Court gutted federal agencies' ability to interpret ambiguous statute.
Pharmacy Times
JULY 3, 2024
The test can be performed in settings that operate under the Clinical Laboratory Improvement Amendments waiver, including community pharmacies.
pharmaphorum
JULY 5, 2024
Discover how innovative approaches and specialised expertise in peptide API synthesis are increasing efficiency and driving advancements in the manufacturing of Active Pharmaceutical Ingredients (API).
STAT
JULY 2, 2024
Eli Lilly’s early Alzheimer’s treatment was approved by the Food and Drug Administration on Tuesday, making it the second drug on the U.S. market aimed at slowing progression of the debilitating neurological disease. The treatment, whose scientific name is donanemab and will be sold under the brand name Kisunla, will compete with Eisai and Biogen’s Leqembi, which got full approval last year.
Expert insights. Personalized for you.
211 
Let's personalize your content